Cidara drug candidates show encouraging action against fungal, viral infections

• Cidara Therapeutics (CDTX +1.0%) announces new data from the Phase 2 STRIVE trial of rezafungin, once-weekly echinocandin for treatment and prevention of fungal infections, and CD377 preclinical data for influenza protection. The results are being presented at IDWeek 2020.
• New analyses from the completed mid-stage study support the efficacy and pharmacokinetics of rezafungin across a wide array of patient populations. The trial demonstrated efficacy across multiple Candida species, with similar or better outcomes observed with rezafungin compared to standard of care, caspofungin.
• In preclinical studies, a single dose of CD377 was protective against seasonal and pandemic influenza subtypes, demonstrating its potent broad-spectrum activity. Showed  superior dose-dependent viral load reduction in the lung compared to approved influenza treatment oseltamivir.
• Cidara is currently conducting two Phase 3 trial with rezafungin - one for the treatment of candidemia and/or invasive candidiasis and another for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation.
• https://seekingalpha.com/news/3624216-cidara-therapeutics-drug-candidates-show-encouraging-action-against-fungal-and-viral